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Abstract. Over the past several years, there has been substan-
tial progress in the field of regenerative medicine, which has 
enabled new possibilities for research and clinical application. 
For example, there are ongoing efforts directed at generating 
functional hepatocytes from adult‑derived pluripotent cells for 
toxicity screening, generating disease models or, in the longer 
term, for the treatment of liver failure. In the present review, 
the authors summarise recent developments in regenerative 
medicine and pluripotent stem cells, the methods and tissues 
used for reprogramming and the differentiation of induced 
pluripotent stem cells (iPSCs) into hepatocyte‑like cells. In 
addition, the hepatic disease models developed using iPSC 
technologies are discussed, as well as the potential for gene 
editing.
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1. Introduction
Although modern medicine has made great progress during the 
last century, there are still few effective ways of treating the 
root cause of many congenital conditions, diseases and inju-
ries. In many cases, clinicians can only manage the symptoms 
exhibited by a patient, and there is a requirement for better 
and safer drugs for treating such conditions. Methods such 
as organ transplantation are increasingly unable to meet the 
needs of patients, due to the lack of sufficient donor organs and 
issues related to immunocompatability. Regenerative medicine 
has the potential to revolutionise drug discovery and clinical 
therapy using stem cells, thereby providing hope for patients 
with conditions that are currently beyond repair.
Pluripotent stem cells are cells that are capable of generating 
daughter cells belonging to any of the three embryonic germ 
layers: The endoderm, mesoderm and ectoderm. The discovery 
of such cells dates back to the 1960s and 1970s, when researchers 
identified that the cells of the inner cell mass of the mouse 
blastocyst were pluripotent in nature (1,2). Further progress 
followed when Evans and Kaufman (3) and Martin (4) isolated 
mouse embryonic stem cells (ESCs), and this was further 
developed by Thomson et al (5) in 1998, who demonstrated a 
culture of human ESCs isolated from human blastocysts that 
offered limitless possibilities for regenerative therapy. However, 
the use of human embryos to generate human ESC lines sparked 
widespread controversy, restricting the research surrounding the 
creation of new human ESC lines. Human ESC lines that were 
already established were later approved for research, yet they 
were limited in number and lacked the diversity necessary to 
address many scientific questions. In addition, most of the human 
ESC lines represented generic genotypes and were not matched 
to a particular disease or patient (6). The immunological issue 
of tissue compatibility and the possibility of tumour formation 
severely restricted their suitability for use in therapy.
In order to capitalise on the potential of these cells, 
researchers tried to develop personalised pluripotent stem 
cells by somatic nuclear transfer without fertilisation. Nuclear 
transfer‑generated pluripotent lines would have the complete 
genome of patients and could be differentiated to specific cell 
types for cell therapy (7). However, the issues of efficiency, 
anxiety over artificially‑created embryos and the potential use 
of such cells for human cloning led to criticism, and research 
in this direction was severely curtailed. In 2006, Takahashi 
and Yamanaka (8) illustrated how to restore pluripotency in 
somatic cells through the ectopic co‑expression of reprogram-
ming factors, rewriting the fundamental idea on the stability of 
cellular identity, thereby providing a strategy to create induced 
pluripotent stem cells (iPSCs). It was a momentous contribu-
tion that provided a new direction for research into disease 
modelling, in vitro differentiation and transdifferentiation, 
and allowed new hope for the development of personalised 
therapies.
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2. Induced pluripotent stem cells
The last decade has seen rapid development in the field of 
stem cells with the advent of human ESCs and, more recently, 
human induced pluripotent stem cells (hiPSCs). Human ESCs 
and hiPSCs can undergo unlimited self‑renewal, retaining 
their potential to differentiate into any type of somatic cell. 
This is a significant achievement, as these iPSCs can provide 
an inexhaustible human cell source (9).
A major advantage of iPSC technology is the ability to 
generate patient‑ or disease‑specific pluripotent stem cells that 
can be grown indefinitely in vitro. This is an invaluable resource 
for medical research, which was previously largely dependent 
on tumour cell lines or transformed derivatives of adult tissues. 
hiPSCs from patients with a variety of genetic diseases, such 
as trisomy 21 syndrome, Parkinson's disease, Huntington 
disease and type 1 diabetes mellitus have been generated (10). 
These disease‑specific stem cells offer a unique opportunity to 
study the diseased cells of a tissue in vitro and may aid the 
development of new drugs for therapeutic intervention.
Advancements in reprogramming technology during the 
last decade have led to the derivation of many hiPSC lines 
that can propagate indefinitely. In order to induce pluripo-
tency in somatic cells multiple transcription factors, the most 
widely used being Oct4, Sox2, Klf4 and c‑Myc, require to be 
transfected into somatic cells. This combination of factors was 
initially identified by Yamanaka's group through the screening 
of 24 pre‑selected factors in a murine system (11), and later, the 
same combination of factors was demonstrated to be sufficient 
for reprogramming human cells (11,12). During reprogram-
ming, DNA methylation and histone modifications occur 
which induce epigenetic changes in the chromatin structure 
thereby mimicking the embryonic stage. However, the exact 
role of transcription factors and their mode of action during 
reprogramming remain elusive and puzzling. Following 
Yamanaka's reports (9,10), different groups have now success-
fully produced hiPSC cells using a variety of starting cell 
types, different combinations of transcription factors and 
different delivery techniques of these factors into the cells.
The potential to use of autologous hiPSCs as therapeutic 
medicines holds tremendous promise. Initially, retroviruses 
were used to introduce transcription factor genes into 
the nucleus of somatic cells. Retroviral methods require 
proliferating cells and have poor transfection efficiency. The 
major disadvantage of the retroviral technique is the potential 
to simultaneously introduce insertional mutations into the 
genome and, thereby, promote tumour formation. This drawback 
shifted the attention of researchers to explore the use of other 
techniques for the insertion of genes, such as lentiviral and 
adenoviral vectors. Lentiviruses can infect non‑proliferating 
cells, and can integrate into the genome of the target cell, 
without expressing viral genes (13,14). However, the limited 
insertion size, difficulty in storage/quality control and safety 
concerns of using virus is the primary drawbacks of using 
this system. Conversely, adenoviral vectors allow transient, 
high‑level expression of exogenous genes without integrating 
into the host genome (15). Adenoviruses have been used to 
generate iPSCs from mouse fibroblasts and liver cells (16). 
Liver cells are highly permissive for adenoviral infections 
and, therefore, less adenovirus is required for the efficient 
reprogramming of liver cells compared with fibroblasts. 
However, the continuous expression of transgenes in iPSCs 
can limit their differentiation potential (17). Many studies have 
explored the removal of viral vectors after reprogramming. 
These techniques include plasmid transfection and piggyback 
transposition system, in which the inserted transgene can be 
subsequently excised to remove the risk of residual expression 
and re‑activation of reprogramming factors (18,19). The risk of 
insertional mutagenesis still remains, as the sequences beyond 
the Lox site cannot be fully excised.
Recently, there have been many studies to identify alterna-
tives to viral vectors for reprogramming somatic cells. Among 
them, the technologies that do not require genome integration 
appear more promising. These technologies include the use of 
small chemical molecules (20), episomal vectors (21), recom-
binant proteins (22), microRNAs (23) and synthetic modified 
mRNAs (24). Owing to its high reproducibility and simplicity, 
the transient transfection technique seems promising and may 
find widespread application.
In addition, different tissue sources have been considered 
for generating iPSCs. Due to the ease of isolation and 
maintenance for reprogramming, the most popular source 
is fibroblasts. Other cell types, including keratinocytes (25), 
mesenchymal stem cells (26), adipose stem cells (27), hair 
follicular cells (28), neural stem cells (29) and urinary 
cells (30), have also been used successfully. A more desirable 
source of starting material is human peripheral blood, 
which can be readily obtained through non‑invasive routine 
clinical procedures. However, the non‑adherent nature of 
most blood cells complicates the process of reprogramming. 
Recently, a robust method for reprogramming peripheral 
blood mononuclear cells using a non‑viral, feeder cell‑free 
methodology has been developed (21).
3. iPS and ES cells, how similar are they?
Even though iPSCs possess phenotypic and behavioural 
similarity to ESCs, recent critical analysis of their genetics 
and epigenetics demonstrates that iPSCs can carry residual 
DNA methylation patterns from their source tissue (31,32). 
Transcribed genes and mutational load have demonstrated 
small distinctive dissimilarities between iPS and ES cells (33), 
and this epigenetic memory can favour the differentiation 
of iPS cells towards the parental cell type. However, this 
phenomenon appears to be transitory in many lines and, in 
some instances, can be erased by additional reprogramming, 
by chromatin‑modifying drugs, or with extended passaging of 
the cells (34). Differences in endogenous signalling activity 
may also contribute to the heterogeneity of iPSC lines gener-
ated from the same tissue sample (35). A recent study on 
variation between pluripotent cell lines indicates that a differ-
ence in genetic background is the major factor for variation, 
rather than aberrations arising during viral transfection (36). 
In the authors' experience, extended passaging of iPSC lines 
did not promote differences in hepatic differentiation, irre-
spective of the parental tissue of origin. However, previous 
work of the University of Edinburgh has observed that iPSCs 
generated using episomal vectors are able to produce healthy 
hepatocyte‑like cells comparable to those produced with lenti-
viral or Sendai vector systems (21).
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Table I. Protocols used to generate hepatic differentiation (3 stage methods).
  Duration
 Signalling molecules  (days) Markers Refs.
Definitive endoderm 100 ng/ml Activin A, 10 µM 6 FOXA2, SOX17 (53)
differentiation LY294002 (inhibit insulin,   
 PI3K/AKT pathway)   
 2 µM bromo‑indirubin‑3'‑oxime   
  (mimic Wnt signalling)
 100 ng/ml Activin A, 50 ng/ml Wnt3A 3 FOXA2, SOX17 (46,53,54) 
 3 µM CHIR99021(mimic 1 FOXA2, SOX17,  (55)
 Wnt signalling)   
 followed by medium alone 1 HHEX, GATA4 
 100 ng/ml Activin A, 100 ng/ml bFGF, 2 SOX17, FOXA2 (56)
 10 ng/ml BMP4, 10 µM LY294002,  and HHEX
 3 µM CHIR99021 (only for 24 h)
 followed by100 ng/ml Activin A,  3
 100 ng/ml bFGF‑1 day
 and 50 ng/ml Activin A
 2 µg/ml CHIR99021 and 1 CXCR4, Ckit,  (57)
 100ng/ml Activin A  SOX17, FOXA1 
 followed by 10.5 ng/ml BMP4, 4  
 10 ng/ml FGF2,
 100 ng/ml Activin A 
 and 10 ng/ml VEGF
 100 ng/ml Activin A 6 HNF3B, CXCR4 (58)
 100 ng/ml Activin A 5  GATA4, SOX17,  (59)
   FOXA2 
Hepatoblast 250 nM sodium butyrate 6‑8  FOXA2, AFP, ALB,  (53) 
 and 0.5% DMSO  HNF4A, CK18, CK19 
 10 ng/ml FGF‑2 and 50 ng/ml BMP‑4 4 FOXA2, AFP, ALB,  (53,54) 
 followed by 50 ng/ml FGF1, 4 HNF4A, CK18, CK19,  
 10 ng/ml FGF 4 and 25 ng/ml FGF8b
 1% DMSO 5 AFP, CEBPA, FOXA2, (46,55) 
    GATA4, HNF4A  
    PROX1, TBX3, TTR  
 20 ng/ml BMP4, 10 ng/ml FGF10 4 HNF4A, PROX1, (56)
   HHEX, AFP, TBX3, 
   FOXA2, AFP, ALB
 50 ng/ml BMP4, 10 ng/ml FGF2,  6 FOXA2, AFP, ALB (57)
 10 ng/ml VEGF, 10 ng/ml EGF,
 20 ng/ml TGFα, 100 ng/ml HGF
 and 0.1 µM Dex
 5 ng/ml FGF4, 10 ng/ml BMP2, 4 HNF4A (58)
 5 ng/ml FGF4, 10 ng/ml BMP2, 
 10 ng/ml BMP4
 20 ng/ml BMP4, 10 ng/ml FGF2 5 FOXA2, HNF4A, AFP (59)
 followed by 20 ng/ml HGF 5 (at 4% O2)
Hepatic maturation 1 µM SB431542 and 1% DMSO 8 ALB, A1AT, ASGPR, (53)
   MRP2, CYP3A4,
   CYP1A1, CYP1A2, urea
 20 ng/ml HGF and 6 ALB, A1AT, ASGPR, (53,54)
 100 ng/ml Follistatin  MRP2, CYP3A4, CYP1A1,
 100 nM DiHexa, 100 nM Dex 10 ALB, HNF4A, A1AT, CYP3A4, (55)
   CYP1A2, Fibronectin
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4. Generating hepatocytes from iPS cells
Under in vivo conditions, stem cells undergo a complex set of 
chemical interactions, switching on or off of various signal-
ling molecules, cell‑cell and cell‑ECM interactions, during 
the process of becoming terminally differentiated cells. It 
is difficult to mimic many of these cues under experimental 
conditions. Some cell types, such as cardiomyocytes, develop 
spontaneously in stem cell culture (at low frequency) while 
other cell types, such as hepatocytes and renal tubular cells, 
require significant technical manoeuvres. Pluripotent stem 
cells certainly appear to progress more efficiently than mesen-
chymal stem cells toward a hepatocyte fate (37).
During embryogenesis, Nodal and Wnt signalling triggers 
endoderm development. Later on in the differentiation process, 
the switching on or off of this signalling regulates endodermal 
tube patterning (34,35). Mesodermal cells surrounding the 
endoderm tube are involved in the hepatic commitment of 
foregut cells (mainly through fibroblast growth factor and bone 
morphogenetic protein signalling) and liver bud formation. 
Later, endothelial cells colonise the liver bud and hepatoblasts 
start to differentiate to biliary cells (hepatoblasts near the 
portal vein) and hepatocytes (38,39).
Researchers have tried to differentiate pluripotent stem 
cells in cell aggregates or as a monolayer. Pluripotent stem 
cells can be aggregated to form embryoid bodies and can be 
differentiated by exposure to specific cytokine and growth 
factor cocktails (40). However, all the existing embryoid 
body‑based protocols suffer from low differentiation effi-
ciency and spontaneous differentiation which gives rise to 
unwanted cell lineages (41‑43). As monolayer culture can be 
adjusted to avoid most of these issues, it has been utilised 
widely and is capable of producing relatively pure populations 
of cells with hepatic function. Among the different approaches 
used to generate hepatocyte‑like cells as monolayers, methods 
mimicking the embryonic developmental stages of the liver 
seem to be the more promising (Table I). Unfortunately, the 
outcome of such approaches varies between different research 
groups for a variety of reasons, including variation in cell 
lines and the conditions used for culture. Efforts have been 
made to optimise the protocol by eliminating the use of poorly 
defined components such as serum, feeder cells, undefined 
culture medium and extracellular matrix to promote consistent 
results (44‑46). A key to the success of these protocols is the 
ability to generate definitive endoderm cells with high effi-
ciency, mainly by using activin A and Wnt3A (47,48), and this 
approach has yielded functionally improved hepatocyte‑like 
cells. Efforts to differentiate iPS cells under 3D dynamic envi-
ronments also helped to enhance the function, but were also 
more like foetal hepatocytes and lacked maturity (49).
Stem cell‑derived hepatocytes have been reported to express 
phase I and II metabolising enzymes, hepatic morphology 
and polarisation, but are still not comparable to primary 
hepatocytes. Hepatic differentiation protocols, evaluation 
strategies and phenotypic or functional outcomes vary widely 
between different laboratories (50). A direct comparison 
of the efficiency of pluripotent stem cell lines to generate 
functional hepatocytes is therefore difficult. As a general 
observation, hiPSC lines present more variable hepatocyte 
differentiation and performance compared with ESC lines, 
Table I. Continued.
  Duration
 Signalling molecules  (days) Markers Refs.
Hepatic maturation 100 ng/ml HGF, 20 ng/ml OSM,  18‑20 ALB, ECAD, CYP3A4, (46) 
 10 µM HC   CYP2D6, MRP1, HNF4A
 50 ng/ml HGF, 30 ng/ml OSM 15 ALB, CK18, A1AT, (56) 
    CYP3A4, LDL uptake,
   TAT, TTR
 10 ng/ml FGF2, 10 ng/ml VEGF, 6 A1AT, ALB, AFP, TTR, (56) 
 10 ng/ml EGF, 100 ng/ml HGF,  fibronectin, transferrin, 
 1.5 µM γ secretase inhibitor,   CYP450
 0.1 µM Dex, 1% DMSO 
 followed by 6
 100 ng/ml HGF, 20 ng/ml OSM 
 6 µg/ml Vitamin K, 0.1 µM Dex
 10 ng/ml HGF, 10 ng/ml OSM, 6 ALB, AAT, CK19, (58) 
 0.1 µM Dex  CK8, CK18, AFP,
 followed by 0.1 µM Dex 5 CYP3A4, CYP1A2 
 20 ng/ml OSM 5 ALB, AFP, HNF4A, (59) 
   FOXA2
bFGF, basic fibroblast growth factor; FGF, fibroblast growth factor; BMP, bone morphogenetic protein; VEGF, vasculalr endothelial growth 
factor; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; TGF‑α, transforming growth factor‑α; HGF, hepatocyte growth factor; Dex, 
dexamethasone; DiHexa, N‑hexanoic‑Tyr‑Ile‑(6) aminohexanoicamide; OSM, oncostatin M; HC, hydrocortisone.
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particularly the H9 line. This may be due to the fact that the 
available differentiation protocols have been developed with 
ESC lines, and these protocols do not address the potential 
retained epigenetic memory or aberrations that iPSC lines 
may possess, making certain that iPSC lines respond weakly 
to hepatic differentiation signals. Moreover, in vitro culture 
itself can induce aberrations in pluripotent cells, and can result 
in significant changes in the differentiation potential within 
different passages of the same cell line (51,52).
5. iPSC-derived hepatocyte-like cells for industry and 
research
The pharmaceutical industries are, at present, reliant primarily 
on animal tests to establish the safety of any new products. 
These tests often fail to predict human toxicity accurately due 
to the physiological differences between humans and animals. 
The advent of iPSCs have offered a new opportunities and 
one would anticipate that in the near future it will be possible 
to perform toxicity screens using iPSC‑derived healthy or 
diseased cells where safety, efficacy, dosage studies and the 
effect of genetics could be studied in human cells before a 
clinical trial.
Severe perturbance in key proteins of metabolic pathways 
can upset hepatocyte homeostasis and can promote liver 
disease (60). Using iPSC technology, it is now possible to 
study, at the cellular level, the pathobiology of genetic liver 
diseases under in vitro conditions. Disease‑specific hiPSCs 
of α1‑antitrypsin deficiency, familial hypercholesterolemia 
and glycogen storage disease type 1a generated from patients 
presented key pathological features of the diseases in in vitro 
culture (61). A later study from the same group demonstrated 
that genetic correction of an α1‑antitrypsin‑deficient 
iPSC line by gene editing could restore the structure and 
function of α1‑antitrypsin in the derived hepatocytes 
both in vitro and in vivo (62), providing hope for future gene 
therapy. A number of iPSC lines from patients suffering from 
tyrosinemia, glycogen storage disease, progressive familial 
hereditary cholestasis and Crigler‑Najjar syndrome have also 
been generated successfully (63). Wilson's disease‑specific 
iPSC lines with the R778L hotspot mutation in the ATP7B 
gene were able to produce hepatocytes with defective copper 
transport in culture (64). The modelling of other inherited 
diseases, such as hemochromatosis, hepatobiliary cystic 
fibrosis and idiosyncratic drug reactions would be helpful for 
understanding the respective disease processes and devising 
clinical interventions. In relation to this, the gene editing 
of iPS cells, not only to correct mutations (62), but also to 
introduce mutations of interest, is an important development 
in disease modelling. Of particular interest in this regard is 
the developing use of CRISPR technology in iPSCs to edit 
genes involved in drug metabolism, thereby providing in vitro 
models relevant to drug development.
6. Discussion
Although significant progress has been made in iPSC 
technology, a full adoption of iPSC‑derived hepatocytes by 
industry will require more robust, consistent and cost effec-
tive protocols, scale‑up and comparative studies with primary 
hepatocytes (65). At present, the state‑of‑the‑art hepatic 
differentiation protocols produce cells, which are foetal in 
both phenotype and function (66). There remains insufficient 
data demonstrating that iPSC‑derived hepatocyte‑like cells are 
comparable to existing primary hepatocyte systems or hepatic 
cell lines, although improved protocols for generating hepato-
cytes are progressing rapidly. Following the establishment of 
improved hepatocyte differentiation protocols, the technology 
for cost‑effective scale‑up conditions that can maintain pheno-
type, function, batch‑to‑batch consistency and reproducibility 
will be required. Given the intensive ongoing research efforts, 
iPSCs will soon be utilised for generating highly predict-
able human hepatic cells of use in determining drug safety, 
as well as for studying the mechanism of action of drugs or 
small molecules and for the generation of new cellular disease 
models.
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